A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Status:
Recruiting
Trial end date:
2028-04-04
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with
placebo in participants with primary progressive multiple sclerosis (PPMS), including
participants later in their disease course. This study focuses on upper limit disability
progression. This study will consist of the following phases: screening, double-blind
treatment, follow-up 1 (FU1), an optional open-label extension (OLE), follow-up 2 (FU2), and
B-cell monitoring (BCM).